Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment

Primary Investigator

Administratively Closed

18 years or above

All

Phase N/A

1000 participants needed

2 Locations

Brief description of study

The primary objectives of the study are:

To longitudinally characterize the long-term effectiveness of DUPIXENT® throughd symptoms, Health-Related Quality of Life (HRQoL) relatedChronic rhinosinusitis with nasal polyposis (CRSwNP) and other type 2 comorbidities,d their change over-time.
To characterize patients who receive DUPIXENT® for CRSwNP in a real-world setting withheir medical history, demographic and disease characteristics, and type 2bidities

The secondary objectives of the study are:

To characterize real-world utilization of DUPIXENT® for patients with CRSwNP
To collect patient and physician global assessment of disease severity and treatmentving DUPIXENT® for CRSwNP
To collect long-term safety data for patients receiving DUPIXENT® for CRSwNP

You may be eligible for this study if you meet the following criteria:

Key Inclusion Criteria:

All patients who are newly initiated on DUPIXENT® for the treatment of CRSwNPding to the respective prescribing information (Product Label or SmPC)
Willing and able to comply with clinic visits and study-related procedures as per
Provide informed consent signed by study patient or legally acceptable representative
Able to understand and complete study-related questionnaires as per protocol

Key Exclusion Criteria:

Patients who have a contraindication to DUPIXENT® according to the country-specificbing information
Any previous treatment with DUPIXENT® for any condition
Any condition that, in the opinion of the investigator, may interfere with thebility to participate in the study per protocol
Participation in an ongoing interventional or observational study that might, in theg physician's opinion, influence the assessments for the current study per

Updated on 13 Dec 2024. Study ID: R668-cSNP-2072, OTHN-REGENERON-AROMA, 16339